Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Clinical Experimentation With Tenofovir Disoproxyl Fumarate and Emtricitabine for COVID-19 (ARTAN-C19)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04712357
Recruitment Status : Recruiting
First Posted : January 15, 2021
Last Update Posted : January 15, 2021
Sponsor:
Collaborators:
Conselho Nacional de Desenvolvimento Científico e Tecnológico
São José Hospital for Infectious Diseases - HSJ
Central Laboratory of Public Health of Ceará - Lacen-CE
Information provided by (Responsible Party):
Aldo Ângelo Moreira Lima, Universidade Federal do Ceara

Brief Summary:
Clinical, control, double-blind, randomized trial with tenofovir disoproxyl fumarate and emtricitabine for Covid-19

Condition or disease Intervention/treatment Phase
Covid19 Drug: Vitamin C 500 MG Oral Tablet Drug: Tenofovir disoproxyl fumarate 300 MG Oral Tablet Drug: Tenofovir disoproxyl fumarate 300 MG plus emtricitabine 200 MG Oral Tablet Not Applicable

Detailed Description:
Several therapeutic agents have been evaluated for the treatment of Covid-19, and only one using an antiviral drug called remdesivir administered intravenously has shown efficacy to reduce the duration of the disease in 26.7% in critically ill patients. This proposal has as its primary objective (a) Determine the effect of TDF and TDF + FTC on the duration of Covid-19 evaluated in the 14th. day of follow-up at the outpatient clinic in the hospital, duration of the disease observing clinical signs and symptoms, as well as evaluating the RT-PCR viral load tests on the 1st, 7th, 14th. and 28th. days of the study protocol. In addition, the proposal assesses several secondary objectives: (b) Assess the action of TDF and TDF + FTC on the immune response using the rapid ELISA test (IgM / IgG) to be performed on the 7th. and 28th. days of monitoring the experimental protocol; (c) Determine the effect of clinical interventions with the drugs TDF and TDF + FTC in the short and medium term on the viral load of SARS-CoV-2; and (d) Assess the effect of TDF and TDF + FTC on inflammation biomarkers cytokines and chemokines (IL-6, MCP-3, D-dimer, IL1-RA, IL-10, GCSF, TNF-α, MCP-1 , IL-2R, MIP-1 alpha, IP-10, IL-8, NT-proBNP, Troponin I, CRP and procalcitonin) in the blood of patients collected in the 1st, 14th. and 28th. study days. The study will be a prospective, double-blind, placebo control and randomized clinical trial of a total of 219 patients with mild to moderate disease, aged 18 years or over, with clinical signs and symptoms of Covid-19 and certified after the RT-PCR test for the detection of SARS-CoV-2 viral load. The study will be carried out at the outpatient clinic of Hospital São José, Fortaleza, CE. The random groups will be: (1) Group - Placebo control (Vitamin C - 500mg / day, for 10 days); (2) Group - tenofovir disoproxyl fumarate (TDF; 300 mg / day, for 10 days); and (3) Group - TDF + emtricitabine (FTC; 200 mg / day, for 10 days). The study aims to evaluate the efficacy of tenofovir alone or combined with emtricitabine in the duration of mild to moderate Covid-19 cases. The study will also assess the effect of drugs on viral load and immune-inflammatory response. In this sense, the study has the perspective of minimizing the evolution of the disease to severe cases, thus relieving the collapse of the health system and minimizing the social, economic and health disorders of the pandemic by SARS-CoV-2.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 219 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Control case
Masking: Double (Participant, Investigator)
Masking Description: Randomized double-blind
Primary Purpose: Treatment
Official Title: Clinical, Control, Double-blind, Randomized Experimentation With Tenofovir Disoproxyl Fumarate and Emtricitabine for COVID-19
Actual Study Start Date : November 9, 2020
Estimated Primary Completion Date : January 2022
Estimated Study Completion Date : January 2023

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Placebo Comparator: Placebo (Vitamin C)
Control placebo (Vitamin C - 500mg / day, for 10 days)
Drug: Vitamin C 500 MG Oral Tablet
Vitamin C 500 MG per day for 10 days

Active Comparator: Tenofovir disoproxyl fumarate (TDF)
Tenofovir disoproxyl fumarate (TDF; 300 mg / day, for 10 days)
Drug: Tenofovir disoproxyl fumarate 300 MG Oral Tablet
Tenofovir disoproxyl fumarate 300 MG per day for 10 days

Active Comparator: TDF + FTC
Tenofovir disoproxyl fumarate (TDF; 300 mg / day, for 10 days) plus emtricitabine (FTC; 200 mg / day, for 10 days)
Drug: Tenofovir disoproxyl fumarate 300 MG plus emtricitabine 200 MG Oral Tablet
Tenofovir disoproxyl fumarate 300 MG plus emtricitabine 200 MG per day for 10 days




Primary Outcome Measures :
  1. The time to recovery, defined at day 7 days follow up after enrollment, on which a patient met the criteria for category 1, 2, or 3 on the eight-category ordinal scale. [ Time Frame: Day 7 follow up after enrollment. ]
    The categories are as follows: 1 - No signals and symptoms; 2 - One signal or symptom; 3 - Two signals or symptoms; 4 - Three or more signals or symptoms; 5 - Hospitalized, no active medical problems; 6 - Hospitalized, not on oxygen; 7 - Hospitalized, on oxygen; and 8 - Hospitalized, on high flow oxygen.


Secondary Outcome Measures :
  1. SARS-CoV-2 RNA viral load measurements change. [ Time Frame: Change between Day 1 and Day 7 follow up after enrollment. ]
    Molecular diagnostic analyzes will be done by Real-Time PCR (qPCR) based on official guidelines determined by the American CDC (CDC-006-00019, Revision: 03; https://www.fda.gov/media/134922/download). The nasopharyngeal swab samples collected (Covid-19 test) will proceed to the nucleic acid isolation (NuAc). All qPCR reactions will be by uniplex diagnosis. Results will be reported in copies of RNA / mL.

  2. Proportion of patients with qualitative serum IgM / IgG. [ Time Frame: Proportion of positive patients at Day 28 for IgM / IgG (N; %). ]
    The IgM / IgG immune response to SARS-CoV-2 will be qualitative measure using rapid diagnostic test provide by Eco Diagnóstica (Nova Lima, MG, Brazil).

  3. Biomarkers (IL-6, MCP-3, D-dimer, IL1-RA, IL-10, GCSF, TNF-α, MCP-1, IL-2R, MIP-1 alpha, IP-10, IL-8, NT-proBNP, Troponin I, CRP and procalcitonin) measurements change. [ Time Frame: Change between Day 1 and Day 14 follow up after enrollment. ]
    We will use the Luminex XMAP Technology (MAGPIX® System, Merck Co., Kenilworth, NJ) which includes the simultaneous analysis, in the same plasma sample (volume of 25 uL), of a panel of protein markers of pro and anti-inflammatory activity (IL-6, MCP-3, D-dimer, IL1-RA, IL-10, GCSF, TNF-α, MCP-1, IL-2R, MIP-1 alpha, IP-10, IL-8, NT-proBNP, Troponin I). Specific antibodies covalently linked to the carboxylated microspheres containing different specific fluorochromes will be used. Standard curves will be constructed for each protein and then their quantification. Results will be reported in pg / mL.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patient is > 18 years old
  • Patient diagnosed with COVID-19

Exclusion Criteria:

  • Patient is already receiving some of the study drugs
  • There is a hospitalization plan in the next 24h
  • Some study treatment is contraindicated
  • Patient has HIV infection
  • Patient has VHB infection
  • Patient lives in another city or state
  • Female patient, pregnant

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04712357


Contacts
Layout table for location contacts
Contact: Aldo AM Lima, Ph.D. 5585987042833 alima@ufc.br
Contact: Alexandre H Binda, Ph.D. 5585987565695 ahavt@ufc.br

Locations
Layout table for location information
Brazil
Núcleo de Biomedicina - NUBIMED Recruiting
Fortaleza, Ceará, Brazil, 60430270
Contact: Aldo A M Lima, PI    +5585987042833    alima@ufc.br   
Contact: Alexandre Havt Bindá, Co-PI    +5585987565695    ahavt@ufc.br   
Principal Investigator: Aldo A M Lima, PI         
Sponsors and Collaborators
Universidade Federal do Ceara
Conselho Nacional de Desenvolvimento Científico e Tecnológico
São José Hospital for Infectious Diseases - HSJ
Central Laboratory of Public Health of Ceará - Lacen-CE
Layout table for additonal information
Responsible Party: Aldo Ângelo Moreira Lima, Principal Investigator, Universidade Federal do Ceara
ClinicalTrials.gov Identifier: NCT04712357    
Other Study ID Numbers: CAAE: 34182620.0.0000.5045
First Posted: January 15, 2021    Key Record Dates
Last Update Posted: January 15, 2021
Last Verified: January 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Aldo Ângelo Moreira Lima, Universidade Federal do Ceara:
Tenofovir
Emtricitabine
COVID-19
Clinical trial
Additional relevant MeSH terms:
Layout table for MeSH terms
Ascorbic Acid
Tenofovir
Emtricitabine
Vitamins
Micronutrients
Nutrients
Growth Substances
Physiological Effects of Drugs
Antiviral Agents
Anti-Infective Agents
Reverse Transcriptase Inhibitors
Nucleic Acid Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-Retroviral Agents
Anti-HIV Agents
Antioxidants
Protective Agents